कंपनी का अवलोकन
GRAIL, Inc. operates as a commercial-stage healthcare entity dedicated to delivering multi-cancer early detection testing and services across the United States and international markets. The company's primary offering, Galleri, serves as a screening solution for asymptomatic individuals aged 50 and older, while also providing a diagnostic aid designed to accelerate cancer detection processes. This business falls within the Healthcare sector, specifically the Diagnostics & Research industry, positioning the firm to capitalize on advancements in genomic medicine and preventive care infrastructure. With a market capitalization of $1.95 billion and an annual revenue of $147.17 million supported by a workforce of 910 employees, the company demonstrates significant scale in a niche but expanding segment. These valuation and revenue figures indicate that GRAIL holds a substantial market presence relative to its peer group, reflecting high investor expectations for the commercialization of its early detection technology despite the current phase of business development.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $147.17 million, yet it recorded a net income loss of $-408,351,008 and an EBITDA of $-377,852,992. The substantial gap between positive revenue and negative net income reveals a heavy cost structure driven by high research and development expenditures and operational scaling costs typical of a commercial-stage biotechnology firm. Free cash flow stands at $-108,893,128, indicating that the company is currently burning cash to fund its growth initiatives rather than generating liquidity from operations. This negative cash flow position limits immediate financial flexibility for acquisitions or dividend payments but is often a strategic choice for companies in the diagnostic research phase. The gross margin is reported at 48.5%, suggesting efficient manufacturing or service delivery costs relative to revenue, whereas the operating margin is significantly depressed at -285.4%, highlighting severe overhead burdens. Furthermore, the profit margin stands at -277.5%, confirming that the company is not yet profitable on a bottom-line basis. On the balance sheet, the company holds $904.43 million in cash against $54.86 million in debt, resulting in a debt-to-equity ratio of 2.13. Despite the elevated leverage ratio, the massive cash reserve suggests a conservative liquidity position relative to immediate obligations, though the high debt-to-equity indicates significant financial leverage. The current ratio of 11.97 points to exceptionally strong short-term liquidity, as current assets vastly exceed current liabilities. However, the return on equity is -16.1% and the return on assets is -11.3%, revealing that management has yet to generate positive returns on shareholder capital or asset base. These negative return metrics reflect the early stage of profitability where capital is being consumed rather than yielding financial returns.
मूल्यांकन आकलन
The P/E ratio on a trailing twelve-month basis is listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at -5.26. The discrepancy between these metrics and the negative earnings trajectory implies that the market is pricing in future earnings potential that has not yet materialized in historical financial statements. The price-to-book ratio is 0.74, which indicates that the company's market valuation is currently below its net asset book value. This suggests the market is not applying a significant premium to the company's tangible assets, a common scenario for growth-stage firms with intangible value not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 13.26 and the EV/EBITDA of -2.92 suggest the market is valuing the company primarily on its revenue generation capabilities rather than current profitability. The stock has traded between a 52-week high of $118.84 and a 52-week low of $20.53, illustrating a wide valuation range driven by volatility in the healthcare technology sector. The current price sits significantly below the 52-week high, reflecting recent market corrections or a lack of immediate catalysts to drive price appreciation toward the upper end of the range. The beta value is listed as N/A, indicating that sufficient historical price data may not be available to calculate volatility relative to the broader market index. Consequently, investors cannot rely on beta to gauge systematic risk for this specific ticker based on standard historical metrics.
Growth & Income
GRAIL, Inc. has achieved a revenue growth rate of 14.0% year-over-year, demonstrating an expanding top line driven by the adoption of its cancer screening tests. However, earnings growth is listed as N/A because the company continues to operate at a loss, meaning earnings are not growing in the traditional sense but rather moving toward breakeven over time. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which aligns with the strategy of reinvesting all available earnings and cash reserves back into research and development. This lack of dividend distribution is typical for commercial-stage healthcare companies that prioritize capital allocation toward scaling operations and technology refinement rather than returning capital to shareholders. The overall growth and income profile is characterized by robust revenue expansion paired with significant negative earnings, reflecting a classic high-growth, early-stage biotechnology business model where profitability is a future milestone rather than a current reality.